Last updated: 2026-09-11 10:29:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Polaryx Therapeutics, Inc. (PLYX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.99, with a market capitalization of $103.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.85 to $48.91. This page covers its latest market performance, valuation, price trends and company information.
$103.68M | |
$1.99 | |
$48.91 | |
$1.85 | |
$1.99 | |
292.00 | |
98.82K | |
-- | |
$48.91 | |
$1.85 | |
-- | |
-- |
Polaryx Therapeutics, Inc. (PLYX) is trading at $1.99 in pre-market trading as of 2026-09-11 08:47:00, unchanged from the previous close of $1.99
Pre-market trading shows how investors are pricing PLYX before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, Polaryx Therapeutics, Inc. (PLYX) moved from $1.98 to $1.99, representing a gain of 0.51% ($0.01).
The stock traded between $1.90 and $2.12 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 33.73 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
PLYX is currently trading at $1.99, placing it 0.3% of the way from its 52-week low of $1.85 to its 52-week high of $48.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Polaryx Therapeutics, Inc. (PLYX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.